Skip to main content

Lymphatic Malformation

1
Pipeline Programs
2
Companies
3
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Avalo Therapeutics
1 program
1
CERC-006Phase 11 trial
Active Trials
NCT04994002Withdrawn0Est. Jun 2022
Protara Therapeutics
1 program
TARA-002PHASE_22 trials
Active Trials
NCT07480356Recruiting284Est. Nov 2032
NCT05871970Recruiting38Est. May 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Protara TherapeuticsTARA-002
Protara TherapeuticsTARA-002
Avalo TherapeuticsCERC-006

Clinical Trials (3)

Total enrollment: 322 patients across 3 trials

NCT07480356Protara TherapeuticsTARA-002

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

Start: May 2026Est. completion: Nov 2032284 patients
Phase 3Recruiting
NCT05871970Protara TherapeuticsTARA-002

Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Start: Oct 2023Est. completion: May 202738 patients
Phase 2Recruiting
NCT04994002Avalo TherapeuticsCERC-006

A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations

Start: Sep 2021Est. completion: Jun 20220
Phase 1Withdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 322 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.